Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, OCT. 23, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF TWO ABSTRACTS FOR ORAL PRESENTATION AND SIX FOR POSTER PRESENTATION AT THE AMERICAN COLLEGE OF ALLERGY, ASTHMA, AND IMMUNOLOGY (ACAAI) 2025 ANNUAL SCIENTIFIC MEETING TO BE HELD FROM NOVEMBER 6-10, IN ORLANDO, FLORIDA.

PHARVARIS TO PRESENT CLINICAL DATA AT THE ACAAI 2025 ANNUAL SCIENTIFIC MEETING

TOPLINE RESULTS FOR RAPIDE-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS, EXPECTED IN 4Q2025 ENROLLMENT CONTINUES IN CHAPTER-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT FOR PROPHYLAXIS OF HAE ATTACKS; TOPLINE RESULTS EXPECTED IN 2H2026 STARTUP ACTIVITIES FOR CREAATE, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT FOR THE PROPHYLACTIC AND ON-DEMAND TREATMENT OF AAE-C1INH ATTACKS, ON TRACK; STUDY IS EXPECTED TO INITIATE BY YE2025 STRONG FINANCIAL POSITION WITH CASH AND CASH EQUIVALENTS OF 200 MILLION AS OF JUNE 30, 2025; SUBSEQUENT CLOSING OF $201 MILLION PUBLIC OFFERING EXTENDS CASH RUNWAY INTO 1H2027 ZUG, SWITZERLAND, AUG. 12, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE. HALFWAY THROUGH 2025, AN IMPORTANT EXECUTIONAL YEAR FOR THE COMPANY, PHARVARIS IS MAKING MEANINGFUL PROGRESS IN OUR AMBITION TO ADDRESS UNMET NEEDS OF PEOPLE LIVING WITH BRADYKININ-MEDIATED ANGIOEDEMA, SAID BERNDT MODIG, CHIEF EXECUTIVE OFFICER OF PHARVARIS.

PHARVARIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ZUG, SWITZERLAND, JULY 22, 2025 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (PHARVARIS, NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN OFFERING OF (I) 8,250,000 OF ITS ORDINARY SHARES AT A PRICE OF $20.00 PER SHARE AND (II) TO ONE INVESTOR, PRE-FUNDED WARRANTS TO PURCHASE 500,000 ORDINARY SHARES AT A PRICE OF $19.99 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE FOR THE ORDINARY SHARES LESS THE $0.01 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. ALL SHARES AND PRE-FUNDED WARRANTS IN THE OFFERING ARE TO BE SOLD BY PHARVARIS. IN ADDITION, PHARVARIS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,312,500 ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS TO PHARVARIS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $175 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 24, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

PHARVARIS ANNOUNCES PRICING OF UPSIZED $175 MILLION PUBLIC OFFERING OF ORDINARY SHARES AND PRE-FUNDED WARRANTS

ZUG, SWITZERLAND, JULY 22, 2025 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (PHARVARIS, NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), ANNOUNCED TODAY THAT IT INTENDS TO OFFER AND SELL $150,000,000 OF ORDINARY SHARES IN AN UNDERWRITTEN PUBLIC OFFERING. ALL SHARES IN THE OFFERING ARE TO BE SOLD BY PHARVARIS. IN ADDITION, PHARVARIS INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $22,500,000 OF ORDINARY SHARES. PHARVARIS CURRENTLY INTENDS TO USE THE NET PROCEEDS OF THIS OFFERING PRIMARILY TO FUND RESEARCH AND DEVELOPMENT EXPENSES FOR ITS LATE-STAGE CLINICAL PROGRAMS, THE HIRING OF A SALES AND MARKETING TEAM IN THE U.S. AND RELATED COMMERCIALIZATION EXPENSES AND FOR WORKING CAPITAL AND GENERAL CORPORATE PURPOSES. THE OFFERING IS SUBJECT TO MARKET CONDITIONS AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

PHARVARIS ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

ZUG, SWITZERLAND, JULY 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), UPDATED THE GUIDANCE FOR THE DISCLOSURE OF TOPLINE DATA FROM THE ONGOING RAPIDE-3 PIVOTAL PHASE 3 STUDY EVALUATING DEUCRICTIBANT IMMEDIATE-RELEASE (IR) CAPSULE FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS. PHARVARIS ANTICIPATES ANNOUNCING TOPLINE DATA FROM RAPIDE-3 IN THE FOURTH QUARTER OF 2025 AND, PENDING POSITIVE DATA, EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN THE FIRST HALF OF 2026.

PHARVARIS UPDATES TIMING OF TOPLINE DATA ANNOUNCEMENT FOR RAPIDE-3 PIVOTAL PHASE 3 STUDY TO THE FOURTH QUARTER OF 2025

ZUG, SWITZERLAND, JUNE 27, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF ABSTRACTS FOR PRESENTATION AT THE US HEREDITARY ANGIOEDEMA ASSOCIATION'S 2025 NATIONAL SUMMIT TO BE HELD FROM JULY 10-13, 2025, IN BALTIMORE, MARYLAND.

PHARVARIS ANNOUNCES CLINICAL TRIAL DATA HIGHLIGHTING DEUCRICTIBANT FOR THE TREATMENT OF HAE TO BE PRESENTED AT THE 2025 US HAEA NATIONAL SUMMIT

ZUG, SWITZERLAND, JUNE 16, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED A SUMMARY OF DATA THAT WERE PRESENTED AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) CONGRESS 2025.

PHARVARIS PRESENTS DATA HIGHLIGHTING THE POTENTIAL FOR DEUCRICTIBANT TO PREVENT AND TREAT BRADYKININ-MEDIATED ANGIOEDEMA ATTACKS AT THE EAACI CONGRESS

ZUG, SWITZERLAND, JUNE 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ANNUAL GENERAL MEETING OF SHAREHOLDERS WILL TAKE PLACE ON FRIDAY, JUNE 27, 2025, AT 16:00 CEST (10:00 A.M. EDT).

PHARVARIS ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS

ZUG, SWITZERLAND, JUNE 02, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED A SUMMARY OF DATA THAT WERE PRESENTED AT THE 14TH C1-INHIBITOR DEFICIENCY AND ANGIOEDEMA WORKSHOP.

PHARVARIS PRESENTS DATA SUPPORTING ONGOING CLINICAL DEVELOPMENT OF DEUCRICTIBANT IN BRADYKININ-MEDIATED ANGIOEDEMA

ZUG, SWITZERLAND, MAY 19, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF ABSTRACTS FOR PRESENTATION AT THREE UPCOMING CONGRESSES: THE 14TH C1-INHIBITOR DEFICIENCY AND ANGIOEDEMA WORKSHOP, TO BE HELD FROM MAY 29-JUNE 1, 2025, IN BUDAPEST; THE 2025 EASTERN ALLERGY CONFERENCE (EAC), TO BE HELD FROM MAY 29-JUNE 1, 2025, IN PALM BEACH, FL.; AND THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) CONGRESS 2025, TO BE HELD FROM JUNE 13-16, 2025, IN GLASGOW.

Pharvaris N.V.

PHVS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Pharvaris N.V.

PHVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PHVS